Document is current
Any future updates will be listed below
-
Authors
Molin, Sonja https://orcid.org/0000-0002-9383-034X
Larsen, Lotte Seiding https://orcid.org/0009-0009-9374-2196
Joensson, Peter https://orcid.org/0009-0004-9609-9072
Oesterdal, Marie Louise
Arbuckle, Rob https://orcid.org/0000-0003-0345-2523
Grant, Laura https://orcid.org/0000-0002-4291-931X
Skingley, George https://orcid.org/0000-0002-7115-0394
Schuttelaar, Marie L. A. https://orcid.org/0000-0002-0766-4382
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03683719 at ClinicalTrials.govnct04871711 at ClinicalTrials.govDocuments that mention this clinical trial
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib Cream
https://doi.org/10.1007/s13555-025-01384-4
Development and Validation of a Patient-Reported Outcome Measure of the Impact of Chronic Hand Eczema on Health-Related Quality of Life: the Hand Eczema Impact Scale (HEIS)
https://doi.org/10.1007/s13555-024-01267-0
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)
https://doi.org/10.1007/s13555-024-01114-2
Documents that mention this clinical trial
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema
https://doi.org/10.1007/s13555-025-01592-y
Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD)
https://doi.org/10.1007/s13555-024-01114-2
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 9 February 2024
First Online: 15 March 2024
Declarations
:
: Sonja Molin has received honoraria as consultant/advisor or speaker and/or grants from Abbvie, Almirall, Aralez, Arcutis, Basilea, Bausch and Lomb, Boehringer-Ingelheim, Bristol Myer Squibb, Evidera, Galderma, GSK, Incyte, LEO Pharma A/S, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma and UCB. She is currently investigator for Novartis and LEO Pharma A/S. Lotte Seiding Larsen was an employee of LEO Pharma A/S at the time the work was conducted and now is an employee of H. Lundbeck A/S, Valby, Denmark. Peter Joensson and Marie Louise Oesterdal are employees of LEO Pharma A/S, Ballerup, Denmark. Rob Arbuckle, Laura Grant and George Skingley are employees of Adelphi Values, a health outcomes agency contracted by LEO Pharma A/S to conduct the research. Marie Lousie Schuttelaar has been a consultant, advisory board member, investigator, and/or speaker for Sanofi, Genzyme, Regeneron Pharmaceuticals, Inc., Pfizer, LEO Pharma A/S, Eli Lilly, Galderma, AbbVie, Novartis, and Amgen. SM, SLS and MLS received no honoraria related to the development of this publication.
: All participants provided informed consent indicating their data will be used for medical research purposes and the study results may be published. The studies were performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Ethical approval and oversight for the qualitative interviews was obtained from Group Copernicus Group Independent Review Board (CGIRB; reference ADE1-17-162). Ethical approval for the psychometric validation activities was obtained as part of the phase 2b (NCT03683719) and phase 3 (NCT04871711) trials from the independent institutional review board (IRB) and ethics committees listed in Table and Table , respectively.
